
China University Student Delivers Baby In Dorm While Preparing For Final Exams
The incident took place at a university in Hubei province where the third-year student unexpectedly went into labour in her room and delivered the baby in her upper bunk bed. Despite being pregnant, the student had insisted on remaining in her upper bunk bed because she found it comfortable.
She went into labour in the middle of the night, and the pungent smell of blood reportedly woke her roommate, who found the student in excruciating pain during childbirth. By the time the medical team arrived, she had already delivered the baby.
Many, including the attending physician, criticised the student's family for failing to provide adequate care for a heavily pregnant woman living in a dorm.
The young mother insisted on completing her final exams before heading to the hospital, explaining that her labour coincided with those exams.
"I didn't anticipate the baby coming so quickly... I assumed I had time and planned to visit the hospital in the morning, but labour progressed extremely fast," she said.
The 20-year-old suffered acute ripping as a result of the baby's size, which was made worse by her high-stress diet and lack of activity during pregnancy.
Following effective bleeding control and recovery confirmation, the mother and baby are currently reported to be in stable condition.
In 2024, a 36-year-old Chinese woman from Hangzhou gave birth to a boy four hours after she became aware of her pregnancy. Doctors were shocked to learn that she was 34 weeks pregnant when she went to the hospital to address her hypertension. The woman, only known by her last name, Gong, was earlier informed that she would never become a mother.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
2 hours ago
- Time of India
US lawmakers press FDA to target knockoff weight-loss drugs
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market-a problem that emerged over the last year. Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity MCA Data Science Degree Leadership PGDM Public Policy Operations Management others Others Product Management healthcare Digital Marketing MBA Technology Project Management CXO Finance Artificial Intelligence Healthcare Data Analytics Management Design Thinking Data Science Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details "We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications," they wrote in a letter to FDA commissioner Marty Makary. "Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo The group-spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey-asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the "urgency" of the situation. Live Events A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a "complete and thorough" response to the issues raised in the lawmakers' letter. "Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously," the spokesperson said. "And we are deeply committed to strengthening the oversight of imported products at US ports of entry." In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalise on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage but are no longer permitted to do so after Novo Nordisk and Eli Lilly boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalisations potentially linked to the copycat drugs, but that adverse events are likely being underreported. "We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs," said a spokesperson for Hims & Hers Health, one of the telehealth firms that sells compounded GLP-1s. "We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first." Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments.


Mint
5 hours ago
- Mint
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. (Updates with statement from FDA in sixth and seventh paragraphs.) More stories like this are available on


News18
5 hours ago
- News18
‘Came With Skills, Heart': Bangladesh's Yunus To Indian, Chinese Doctors Treating Crash Victims
Last Updated: The international medical teams are currently in Dhaka to provide specialised care to those injured in the recent plane crash, many of whom are children Bangladesh's interim leader Muhammad Yunus on Sunday thanked doctors and nurses from India, China, and Singapore for their support in treating victims of the recent plane crash in Dhaka. In a post on the social media platform X, Yunus said that a delegation of 21 doctors and nurses from the three countries met him at the State Guest House Jamuna in Dhaka. The international medical teams are in the capital to provide specialised care to those injured in the crash at Milestone School and College, many of whom are children. The crash took place on Monday when a Chinese-made F-7 BGI training fighter jet suffered a mechanical fault shortly after take-off and crashed into a two-storey school building, killing 32 people, including 26 children. 'These teams have come not just with their skills, but with their hearts," Yunus said during the meeting. 'Their presence reaffirms our shared humanity and the value of global partnerships in times of tragedy." Chief Adviser thanks foreign medical teams for treating plane crash victimsDhaka, July 27, 2025: A delegation of 21 physicians and nurses from Singapore, China, and India met with Chief Adviser Professor Muhammad Yunus on Sunday at the State Guest House Jamuna. The… — Chief Adviser of the Government of Bangladesh (@ChiefAdviserGoB) July 27, 2025 The interim leader praised the teams' quick response and dedication during a national crisis and assured the visiting medical professionals of the government's full support in helping them carry out their mission. He also urged the doctors to build long-term ties with Bangladesh, including virtual cooperation in areas such as institutional collaboration, medical education exchange, and capacity building in the health sector. 'He emphasised that such partnerships could lay the foundation for lasting cooperation in public health and emergency preparedness," the post added. The delegation included ten members from Singapore, eight from China, and four from India. Chinese Ambassador to Dhaka Yao Wen and the Head of Mission from Singapore also attended the meeting. Meanwhile, an Indian medical team had arrived in Dhaka on Wednesday to assist in treating the victims of the crash. Prime Minister Narendra Modi had also expressed his condolences over the loss of life and offered support and assistance to Bangladesh following the tragedy. view comments Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.